Xenetic Biosciences, Inc. — 2018 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2018. This is an annual filing, not a standalone fourth-quarter report. Financial comparisons are to fiscal 2017. The company is a clinical-stage biopharmaceutical developer; it had no approved products and no 2018 revenue.
Financial performance and position
| Metric | 2018 | 2017 |
|---|---|---|
| Revenue | $0 | $7.585 million |
| Research and development expense | $2.884 million | $4.060 million |
| General and administrative expense | $4.392 million | $6.938 million |
| Operating loss | $7.276 million | $3.569 million |
| Net loss | $7.300 million | $3.595 million |
| Basic and diluted loss per share | $0.80 | $0.41 |
| Cash used in operating activities | $6.464 million | Cash provided: $1.494 million |
- The 2017 revenue included a one-time $7.5 million sublicense payment from Takeda and $85,000 of collaboration-services revenue. No license or collaboration-services revenue was recorded in 2018. No Takeda sublicense royalties had been received by the filing date.
- R&D expense fell 29% and G&A fell 36.7%, reflecting narrower development activity and reduced discretionary spending amid capital constraints. The disappearance of 2017 revenue drove the increase in net loss despite lower expenses.
- At December 31, 2018, cash was $571,605, with a further $66,510 of restricted cash. Working capital was a deficit of approximately $0.4 million, versus a $3.9 million surplus a year earlier. Current liabilities were $1.600 million; total liabilities were $4.518 million, including a $2.919 million deferred tax liability. The balance sheet does not present a separate borrowing balance.
- Accumulated deficit was $153.2 million. There was no material capital-expenditure commitment reported at year-end. Cash from financing activities was $1.480 million, from warrant exercises.
- Margins are not meaningful for 2018 because the company reported no revenue. In 2017, revenue was largely a one-time sublicense receipt rather than recurring product sales.
Material changes, outlook and risks
- Going concern and funding: Management and the auditor said substantial doubt exists about the company’s ability to continue as a going concern, citing recurring losses and negative operating cash flows. The company estimated year-end resources would fund planned operations and obligations only through the first half of 2019 and had no committed future funding. On March 5, 2019, it raised approximately $3.1 million gross, or $2.7 million net, in a registered direct offering. Management said additional capital or strategic alternatives would still be needed.
- XBIO-101: The Phase II trial for progestin-resistant endometrial cancer began dosing in October 2017. Enrollment was closed in March 2019 because of slow enrollment and retention. The company was evaluating alternative development paths, including possible immuno-oncology applications and partner-led work; timing and funding were uncertain.
- Proposed XCART acquisition: On March 1, 2019, the company agreed to acquire a personalized CAR T platform, with a proposed issuance of 7.5 million common shares. Closing was expected in the first half of 2019, subject to stockholder approval, adequate post-closing working capital and other conditions. The technology’s claimed potential was preclinical; further development, regulatory approval and commercialization were uncertain.
- Pipeline and collaboration risks: Internal 2018 development was focused on XBIO-101 due to capital constraints; OncoHist development was on hold, and ErepoXen internal clinical development had been terminated. Takeda had discontinued SHP656 development in 2017 after it did not meet a predefined once-weekly dosing criterion. Future collaboration milestones and royalties were uncertain, and the company said it did not expect near-term payments other than possible royalties under the Takeda sublicense.
- Other investor considerations: The company relies on third-party manufacturers, CROs and collaborators and had four full-time employees at year-end. Pharmsynthez held approximately 57.1% of outstanding common stock at December 31, 2018. Preferred stock, outstanding warrants/options and the proposed acquisition shares create potential dilution; Series B preferred stock also has anti-dilution provisions. Goodwill of $3.283 million and indefinite-lived IPR&D assets of $9.243 million were not impaired in 2018, but their recoverability depends on development success and future financing.
- The auditor issued an unmodified opinion on the financial statements with a going-concern explanatory paragraph. Management reported disclosure controls and internal control over financial reporting were effective as of year-end; the auditor did not attest to internal-control effectiveness.
- The filing identifies no material legal proceeding as of December 31, 2018. A 2015 supplier dispute was settled in 2017 for approximately $0.6 million.
Most important facts for investors to verify
- Whether additional financing is secured and sufficient to fund operations, the XCART transaction and development plans beyond the stated first-half 2019 runway.
- Whether the XCART acquisition closed, its final share issuance and financing terms, and the actual development evidence and costs for the platform.
- XBIO-101’s development strategy after enrollment closed, including any clinical data, partner commitments, timelines and funding requirements.
- Current cash, working capital, operating cash burn and any new debt, equity issuance or strategic financing since the reporting date.
- Potential dilution from the proposed 7.5 million transaction shares, the March 2019 financing and outstanding convertible preferred stock, warrants and options.
- Whether the carrying values of goodwill and IPR&D remain supportable as development and financing assumptions change.